Human Genome Epidemiology Literature Finder
|
Records 1 - 22 (of 22 Records) |
| Query Trace: Neuroendocrine Tumors and DAXX[original query] |
|---|
| DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (New York, N.Y.) 2011 1 331 (6021): 1199-203. Jiao Yuchen, Shi Chanjuan, Edil Barish H, de Wilde Roeland F, Klimstra David S, Maitra Anirban, Schulick Richard D, Tang Laura H, Wolfgang Christopher L, Choti Michael A, Velculescu Victor E, Diaz Luis A, Vogelstein Bert, Kinzler Kenneth W, Hruban Ralph H, Papadopoulos Nickol |
| KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors. International journal of biological sciences 2014 10 (9): 957-65. Yuan Fei, Shi Min, Ji Jun, Shi Hailong, Zhou Chenfei, Yu Yingyan, Liu Bingya, Zhu Zhenggang, Zhang J |
| Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Jul . Singhi Aatur D, Liu Ta-Chiang, Roncaioli Justin L, Cao Dengfeng, Zeh Herbert J, Zureikat Amer H, Tsung Allan, Marsh J Wallis, Lee Kenneth K, Hogg Melissa E, Bahary Nathan, Brand Randall, McGrath Kevin M, Slivka Adam, Cressman Kristi L, Fuhrer Kimberly, O'Sullivan Roderick |
| Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. International journal of biological sciences 2016 12 (12): 1523-1532. Chou Wen-Chi, Lin Po-Han, Yeh Yi-Chen, Shyr Yi-Ming, Fang Wen-Liang, Wang Shin-E, Liu Chun-Yu, Chang Peter Mu-Hsin, Chen Ming-Han, Hung Yi-Ping, Li Chung-Pin, Chao Yee, Chen Ming-Hua |
| Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region. The American journal of surgical pathology 2017 Jul . Casar-Borota Olivera, Botling Johan, Granberg Dan, Stigare Jerker, Wikström Johan, Boldt Henning Bünsow, Kristensen Bjarne Winther, Pontén Fredrik, Trouillas Jacqueli |
| Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. Oncotarget 2017 Nov 8 (55): 93464-93475. Gleeson Ferga C, Voss Jesse S, Kipp Benjamin R, Kerr Sarah E, Van Arnam John S, Mills John R, Marcou Cherisse A, Schneider Amber R, Tu Zheng Jin, Henry Michael R, Levy Michael |
| ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. Human pathology 2018 Aug . Chou Angela, Itchins Malinda, de Reuver Philip R, Arena Jennifer, Clarkson Adele, Sheen Amy, Sioson Loretta, Cheung Veronica, Perren Aurel, Nahm Christopher, Mittal Anubhav, Samra Jaswinder S, Pajic Marina, Gill Anthony |
| Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times. Gastroenterology 2018 2 154 (8): 2060-2063.e8. Roy Somak, LaFramboise William A, Liu Ta-Chiang, Cao Dengfeng, Luvison Alyssa, Miller Caitlyn, Lyons Maureen A, O'Sullivan Roderick J, Zureikat Amer H, Hogg Melissa E, Tsung Allan, Lee Kenneth K, Bahary Nathan, Brand Randall E, Chennat Jennifer S, Fasanella Kenneth E, McGrath Kevin, Nikiforova Marina N, Papachristou Georgios I, Slivka Adam, Zeh Herbert J, Singhi Aatur |
| DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression. Journal of vascular and interventional radiology : JVIR 2018 11 29 (11): 1519-1526. Ziv Etay, Rice Samuel L, Filtes John, Yarmohammadi Hooman, Boas F Edward, Erinjeri Joseph P, Petre Elena Nadia, Brody Lynn A, Brown Karen T, Covey Anne M, Getrajdman George I, Maybody Majid, Raj Nitya, Sofocleous Constantinos T, Solomon Stephen B, Reidy-Lagunes Dia |
| Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Annals of surgery 2018 10 271 (3): 566-573. Pea Antonio, Yu Jun, Marchionni Luigi, Noe Michael, Luchini Claudio, Pulvirenti Alessandra, de Wilde Roeland F, Brosens Lodewijk A, Rezaee Neda, Javed Ammar, Chianchiano Peter, Gobbo Stefano, Regi Paolo, Salvia Roberto, Bassi Claudio, He Jin, Weiss Matthew J, Cameron John L, Offerhaus G Johan A, Hruban Ralph H, Lawlor Rita T, Scarpa Aldo, Heaphy Christopher M, Wood Laura D, Wolfgang Christopher |
| Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors. Annals of surgery 2019 10 274 (6): e949-e956. Uemura Jun, Okano Keiichi, Oshima Minoru, Suto Hironobu, Ando Yasuhisa, Kumamoto Kensuke, Kadota Kyuichi, Ichihara Shuji, Kokudo Yasutaka, Maeba Takashi, Nanno Yoshihide, Toyama Hirochika, Takada Yasutsugu, Shimada Mitsuo, Hanazaki Kazuhiro, Masaki Tsutomu, Suzuki Yasuyu |
| Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO precision oncology 2019 1 2018 . Raj Nitya, Shah Ronak, Stadler Zsofia, Mukherjee Semanti, Chou Joanne, Untch Brian, Li Janet, Kelly Virginia, Saltz Leonard B, Mandelker Diana, Ladanyi Marc, Berger Michael F, Klimstra David S, Reidy-Lagunes Diane, Osoba Muyin |
| Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort. Neuroendocrinology 2021 8 112 (5): 510-522. Ban Xinchao, Mo Shengwei, Lu Zhaohui, Jia Congwei, Shao Huilin, Yan Jie, Chang Xiaoyan, Mao Xinxin, Wu Yan, Zhang Yue, Fan Xiaojie, Yu Shuangni, Chen J |
| Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis. Frontiers in endocrinology 2021 12 691557. Wang Fei, Xu Xiaowu, Ye Zeng, Qin Yi, Yu Xianjun, Ji Shunro |
| DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications biology 2021 2 4 (1): 155. Lakis Vanessa, Lawlor Rita T, Newell Felicity, Patch Ann-Marie, Mafficini Andrea, Sadanandam Anguraj, Koufariotis Lambros T, Johnston Rebecca L, Leonard Conrad, Wood Scott, Rusev Borislav, Corbo Vincenzo, Luchini Claudio, Cingarlini Sara, Landoni Luca, Salvia Roberto, Milella Michele, Chang David, Bailey Peter, Jamieson Nigel B, Duthie Fraser, Gingras Marie-Claude, Muzny Donna M, Wheeler David A, Gibbs Richard A, Milione Massimo, , , Pederzoli Paolo, Samra Jaswinder S, Gill Anthony J, Johns Amber L, Pearson John V, Biankin Andrew V, Grimmond Sean M, Waddell Nicola, Nones Katia, Scarpa Al |
| Sex-Based Clinicopathologic and Survival Differences Among Patients with Pancreatic Neuroendocrine Tumors. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2022 8 26 (11): 2321-2329. Greenberg Jacques A, Ivanov Nikolay A, Egan Caitlin E, Lee Yeon Joo, Zarnegar Rasa, Fahey Thomas J, Finnerty Brendan M, Min Irene |
| Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors. European journal of endocrinology 2022 5 187 (1): 85-90. Ling Chao, Hong Xiafei, Xu Mengyue, Wang Yutong, Ma Xiaosen, Cui Yunying, Jiang Rui, Cao Dingyan, Wu Huanwen, Tong Anli, Zhao Yupei, Wu Wenmi |
| Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). Diagnostics (Basel, Switzerland) 2023 5 13 (9): . Giuseppe Lamberti, Natalie Prinzi, Alberto Bongiovanni, Mariangela Torniai, Elisa Andrini, Dario de Biase, Deborah Malvi, Mirta Mosca, Rossana Berardi, Toni Ibrahim, Sara Pusceddu, Davide Campa |
| Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. Cancers 2024 9 16 (17): . Rushabh Gujarathi, Joseph Tobias, Sara Abou Azar, Xavier M Keutgen, Chih-Yi Li |
| MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocrine-related cancer 2024 8 . Rushabh Gujarathi, Sara Abou Azar, Joseph Tobias, Blase N Polite, Namrata Setia, Nicholas Feinberg, Daniel E Appelbaum, Xavier Keutgen, Chih-Yi Li |
| DAXX is associated with early recurrence of pancreatic neuroendocrine tumors after R0 resection. Surgery 2024 10 . Benjamin C Greenspun, Amanda Foshag, Abhinay Tumati, Teagan Marshall, Dongxiang Xue, Liuliu Yang, Shuibing Chen, Rasa Zarnegar, Thomas J Fahey, Brendan M Finner |
| Comparative targeted genome profiling between solid and liquid biopsies in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a proof-of-concept pilot study. Neuroendocrinology 2024 10 1-20. Irene Gagliardi, Federica Campolo, Patricia Borges de Souza, Lucrezia Rossi, Manuela Albertelli, Federica Grillo, Luigi Caputi, Massimiliano Mazza, Antongiulio Faggiano, Maria Chiara Zatel |
- Page last reviewed:Feb 1, 2024
- Content source: